Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Short-term Investments (2016 - 2025)

Historic Short-term Investments for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q3 2025 value amounting to $156.6 million.

  • Enanta Pharmaceuticals' Short-term Investments fell 2578.16% to $156.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $156.6 million, marking a year-over-year decrease of 2578.16%. This contributed to the annual value of $156.6 million for FY2025, which is 2578.16% down from last year.
  • Enanta Pharmaceuticals' Short-term Investments amounted to $156.6 million in Q3 2025, which was down 2578.16% from $159.3 million recorded in Q2 2025.
  • In the past 5 years, Enanta Pharmaceuticals' Short-term Investments ranged from a high of $298.8 million in Q1 2021 and a low of $132.3 million during Q4 2024
  • Moreover, its 5-year median value for Short-term Investments was $205.2 million (2022), whereas its average is $209.1 million.
  • Data for Enanta Pharmaceuticals' Short-term Investments shows a peak YoY increase of 7294.2% (in 2024) and a maximum YoY decrease of 5547.31% (in 2024) over the last 5 years.
  • Over the past 5 years, Enanta Pharmaceuticals' Short-term Investments (Quarter) stood at $160.0 million in 2021, then increased by 7.67% to $172.2 million in 2022, then skyrocketed by 72.55% to $297.2 million in 2023, then crashed by 55.47% to $132.3 million in 2024, then rose by 18.3% to $156.6 million in 2025.
  • Its last three reported values are $156.6 million in Q3 2025, $159.3 million for Q2 2025, and $133.2 million during Q1 2025.